Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Metabolic Profiling of IDH Mutation and Malignant Progression in Infiltrating Glioma.

Jalbert LE, Elkhaled A, Phillips JJ, Neill E, Williams A, Crane JC, Olson MP, Molinaro AM, Berger MS, Kurhanewicz J, Ronen SM, Chang SM, Nelson SJ.

Sci Rep. 2017 Mar 22;7:44792. doi: 10.1038/srep44792.

2.

Understanding the Intersections between Metabolism and Cancer Biology.

Vander Heiden MG, DeBerardinis RJ.

Cell. 2017 Feb 9;168(4):657-669. doi: 10.1016/j.cell.2016.12.039. Review.

PMID:
28187287
3.

Edited 1 H magnetic resonance spectroscopy in vivo: Methods and metabolites.

Harris AD, Saleh MG, Edden RA.

Magn Reson Med. 2017 Apr;77(4):1377-1389. doi: 10.1002/mrm.26619. Epub 2017 Feb 2. Review.

PMID:
28150876
4.

Interrogating IDH Mutation in Brain Tumor: Magnetic Resonance and Hyperpolarization.

Hu J, Salzillo TC, Sailasuta N, Lang FF, Bhattacharya P.

Top Magn Reson Imaging. 2017 Feb;26(1):27-32. doi: 10.1097/RMR.0000000000000113.

PMID:
28079713
5.

Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions.

Vernieri C, Casola S, Foiani M, Pietrantonio F, de Braud F, Longo V.

Cancer Discov. 2016 Dec;6(12):1315-1333. Epub 2016 Nov 21. Review.

PMID:
27872127
6.

MR Molecular Imaging of Brain Cancer Metabolism Using Hyperpolarized 13C Magnetic Resonance Spectroscopy.

Najac C, Ronen SM.

Top Magn Reson Imaging. 2016 Oct;25(5):187-196. Review.

PMID:
27748711
7.

Metabolic Imaging in Humans.

Fuss TL, Cheng LL.

Top Magn Reson Imaging. 2016 Oct;25(5):223-235. Review.

PMID:
27748708
8.

Introduction of High Throughput Magnetic Resonance T2-Weighted Image Texture Analysis for WHO Grade 2 and 3 Gliomas.

Kinoshita M, Sakai M, Arita H, Shofuda T, Chiba Y, Kagawa N, Watanabe Y, Hashimoto N, Fujimoto Y, Yoshimine T, Nakanishi K, Kanemura Y.

PLoS One. 2016 Oct 7;11(10):e0164268. doi: 10.1371/journal.pone.0164268. eCollection 2016.

9.

Non-invasive detection of 2-hydroxyglutarate in IDH-mutated gliomas using two-dimensional localized correlation spectroscopy (2D L-COSY) at 7 Tesla.

Verma G, Mohan S, Nasrallah MP, Brem S, Lee JY, Chawla S, Wang S, Nagarajan R, Thomas MA, Poptani H.

J Transl Med. 2016 Sep 22;14(1):274.

10.

IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives.

Mondesir J, Willekens C, Touat M, de Botton S.

J Blood Med. 2016 Sep 2;7:171-80. doi: 10.2147/JBM.S70716. eCollection 2016. Review.

11.

In-Vivo Proton Magnetic Resonance Spectroscopy of 2-Hydroxyglutarate in Isocitrate Dehydrogenase-Mutated Gliomas: A Technical Review for Neuroradiologists.

Kim H, Kim S, Lee HH, Heo H.

Korean J Radiol. 2016 Sep-Oct;17(5):620-32. doi: 10.3348/kjr.2016.17.5.620. Epub 2016 Aug 23. Review.

12.

Improved localisation for 2-hydroxyglutarate detection at 3T using long-TE semi-LASER.

Berrington A, Voets NL, Plaha P, Larkin SJ, Mccullagh J, Stacey R, Yildirim M, Schofield CJ, Jezzard P, Cadoux-Hudson T, Ansorge O, Emir UE.

Tomography. 2016 Jun;2(2):94-105.

13.

Loss of ATRX and DAXX expression identifies poor prognosis for smooth muscle tumours of uncertain malignant potential and early stage uterine leiomyosarcoma.

Slatter TL, Hsia H, Samaranayaka A, Sykes P, Clow WB, Devenish CJ, Sutton T, Royds JA, Pc P, Cheung AN, Hung NA.

J Pathol Clin Res. 2015 Mar 16;1(2):95-105. doi: 10.1002/cjp2.11. eCollection 2015 Apr.

14.

Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring.

Chaumeil MM, Radoul M, Najac C, Eriksson P, Viswanath P, Blough MD, Chesnelong C, Luchman HA, Cairncross JG, Ronen SM.

Neuroimage Clin. 2016 Jun 23;12:180-9. doi: 10.1016/j.nicl.2016.06.018. eCollection 2016.

15.

Non-invasive metabolic imaging of brain tumours in the era of precision medicine.

Kim MM, Parolia A, Dunphy MP, Venneti S.

Nat Rev Clin Oncol. 2016 Dec;13(12):725-739. doi: 10.1038/nrclinonc.2016.108. Epub 2016 Jul 19. Review.

PMID:
27430748
16.

Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients.

Jafari-Khouzani K, Loebel F, Bogner W, Rapalino O, Gonzalez GR, Gerstner E, Chi AS, Batchelor TT, Rosen BR, Unkelbach J, Shih HA, Cahill DP, Andronesi OC.

Neuro Oncol. 2016 Nov;18(11):1569-1578. Epub 2016 Jul 5.

PMID:
27382115
17.

Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas.

Zhang B, Chang K, Ramkissoon S, Tanguturi S, Bi WL, Reardon DA, Ligon KL, Alexander BM, Wen PY, Huang RY.

Neuro Oncol. 2017 Jan;19(1):109-117. doi: 10.1093/neuonc/now121. Epub 2016 Jun 26.

PMID:
27353503
18.

Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma.

Nagashima H, Tanaka K, Sasayama T, Irino Y, Sato N, Takeuchi Y, Kyotani K, Mukasa A, Mizukawa K, Sakata J, Yamamoto Y, Hosoda K, Itoh T, Sasaki R, Kohmura E.

Neuro Oncol. 2016 Nov;18(11):1559-1568. Epub 2016 May 5.

PMID:
27154922
19.

Molecular Imaging of Metabolic Reprograming in Mutant IDH Cells.

Viswanath P, Chaumeil MM, Ronen SM.

Front Oncol. 2016 Mar 14;6:60. doi: 10.3389/fonc.2016.00060. eCollection 2016. Review.

20.

In vivo detection of 2-hydroxyglutarate in brain tumors by optimized point-resolved spectroscopy (PRESS) at 7T.

Ganji SK, An Z, Tiwari V, McNeil S, Pinho MC, Pan E, Mickey BE, Maher EA, Choi C.

Magn Reson Med. 2017 Mar;77(3):936-944. doi: 10.1002/mrm.26190. Epub 2016 Mar 16.

PMID:
26991680

Supplemental Content

Support Center